Entresto vs Ibrance
Side-by-side drug price comparison from Medicare Part D data
Verdict
Entresto costs 96% less per claim than Ibrance ($379.00 vs $10816.00). Ibrance has a generic alternative available. Total Medicare spending: Entresto at $4.8B vs Ibrance at $4.5B.
| Metric | Entresto | Ibrance |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $379* | $10,816 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $4.8B | $4.5B |
| Total Claims | 12,560,000 | 418,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 18.3% | -5.6%* |
| Generic Available | No | Yes |
| Condition | Heart Failure | Cancer |
| Total Beneficiaries | 1,085,000 | 36,000 |
Entresto costs 96% less per claim than Ibrance ($379.00 vs $10816.00). Ibrance has a generic alternative available. Total Medicare spending: Entresto at $4.8B vs Ibrance at $4.5B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Entresto and Ibrance. What follows is the interpretation — which specific axes carry the most weight for Entresto versus Ibrance, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.